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Endoplasmic reticulum (ER) protein sigma-1 receptor represents unique chaperone activity in the central
nervous system, and it exerts a potent inﬂuence on a number of neurotransmitter systems. Several lines
of evidence suggest that activation of sigma-1 receptor plays a role in the pathophysiology of neuro-
psychiatric diseases, as well as in the mechanisms of some therapeutic drugs and neurosteroids. Pre-
clinical studies showed that some selective serotonin reuptake inhibitors (SSRIs; ﬂuvoxamine, ﬂuoxetine,
excitalopram), donepezil, and ifenprodil act as sigma-1 receptor agonists. Furthermore, sigma-1 receptor
agonists could improve the N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP)-induced
cognitive deﬁcits in mice. A study using positron emission tomography have demonstrated that an
oral administration of ﬂuvoxamine or donepezil could bind to sigma-1 receptor in the healthy human
brain, suggesting that sigma-1 receptor might be involved in the therapeutic mechanisms of these drugs.
Moreover, case reports suggest that sigma-1 receptor agonists, including ﬂuvoxamine, and ifenprodil,
may be effective in the treatment of cognitive impairment in schizophrenia, delirium in elderly people,
and ﬂashbacks in post-traumatic stress disorder. In this review article, the author would like to discuss
the clinical implication of sigma-1 receptor agonists, including endogenous neurosteroids, in the
neuropsychiatric diseases.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sigma receptors were proposed by Martin and coworkers in
1976, and were initially considered a subclass (sigma opioid re-
ceptor) of opioid receptors. A subsequent study reported that sigma
receptors interact with endogenous neurosteroids, suggesting a
link between endocrine, nervous, and immune systems (1). Sigma
receptors consist of at least two subtypes, sigma-1 and sigma-2. In
1996, sigma-1 receptor was successfully cloned and is a 223 amino
acid protein with two transmembrane domains (2). In 2007, sigma-
1 receptor was later identiﬁed as a ligand-responsive endoplasmic
reticulum (ER) chaperone residing speciﬁcally at the ER-
mitochondrion interface (3,4). In its dormant state, the sigma-1
receptor forms a complex with another chaperone bindingy Center for Forensic Mental
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regulated protein (GRP78), in the lumen of the ER. The presence
of sigma-1 receptor agonists can trigger dissociation of the sigma-1
receptor from BiP, activating the sigma-1 receptor chaperone
(Fig. 1)(3,4).
Accumulating evidence suggests that sigma-1 receptor regu-
lates a variety of cellular functions, such as inositol 1,4,5-triphos-
phate (IP3) receptor-mediated Ca2þ signaling, ion channel ﬁring,
protein kinase location/activation, cellular redox, neurotransmitter
release, inﬂammation, cellular differentiation, neuronal survival
and synaptogenesis (3e5). Furthermore, sigma-1 receptor plays an
important role in neuronal plasticity, a process implicated in the
pathophysiology of neuropsychiatric diseases (5e9).
Activation of ligand-responsive sigma-1 receptor by agonists is
likely to have beneﬁcial effects in the cells. Currently, some thera-
peutic drugs (e.g., ﬂuvoxamine, ﬂuoxetine, escitalopram, donepezil,
ifenprodil), which have been used in humans, and some endoge-
nous neurosteroids (e.g., dehydroepiandosterone (DHEA)) have
high to moderate afﬁnity at sigma-1 receptor. In this review, we
discuss about clinical implication of sigma-1 receptor agonists in
the neuropsychiatric diseases.vier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. A possible therapeutic mechanism for sigma-1 receptor agonists in neuropsychiatric diseases. Stimuli such as oxidative stress, inﬂammation, disturbances in Ca2þ
homeostasis, and enhanced expression of normal and/or folding-defective proteins may lead to the accumulation of unfolded proteins, a condition referred to as ER stress, and,
ultimately, to the development of neuropsychiatric diseases. Cognitive impairment is shown in patients with a number of neuropsychiatric diseases including schizophrenia, major
depressive disorder (MDD), bipolar disorder, generalized anxiety disorder (GAD), panic disorder, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD),
attention deﬁcit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), post-stroke depression, and delirium. In control states, the sigma-1 receptor forms a complex with
another ER chaperone, BiP (GRP78). Sigma-1 receptor agonists, such as ﬂuvoxamine, ﬂuoxetine, escitalopram, donepezil, ifenprodil, DHEA (or DHEA-S), and pregnenolone, bind to
sigma-1 receptors on the ER, and promote dissociation of the sigma-1 receptor from its complex with BiP (3e5). This dissociated sigma-1 receptor is free to stimulate chaperone
activity, resulting in neuroprotection. This represents a slight modiﬁcation from Hayashi et al. (5) and Hashimoto (9).
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Some selective serotonin reuptake inhibitors (SSRIs), including
ﬂuvoxamine, sertraline, ﬂuoxetine, escitalopram, and citalopram,
have high to moderate afﬁnity at sigma-1 receptor (10,11). The or-
der of potency for SSRIs at sigma-1 receptor is as follows: ﬂuvox-
amine (Ki ¼ 17.0 nM) > sertraline (Ki ¼ 31.6 nM) > ﬂuoxetine
(Ki ¼ 191.2 nM) > escitalopram (Ki ¼ 288.3 nM) > citalopram
(Ki ¼ 403.8 nM)[ paroxetine (Ki ¼ 2041 nM)(Table 1) (11). In
contrast, serotonin and norepinephrine reuptake inhibitors (SNRIs)
and new antidepressant mirtazapine have no afﬁnity at sigma-1
receptors (Table 1)(11). We reported that some SSRIs (ﬂuvox-
amine, ﬂuoxetine, escitalopram) signiﬁcantly could potentiateTable 1
Afﬁnity of antidepressants for sigma-1 receptor chaperone.
Drugs Ki (nM) Pharmacology at sigma-1 receptor
Fluvoxamine (SSRI) 17.0 Agonist
Sertraline (SSRI) 31.6 Antagonist?
Fluoxetine (SSRI) 191.2 Agonist
Escitalopram (SSRI) 288.3 Agonist
Citalopram (SSRI) 403.8 Agonist
Paroxetine (SSRI) 2041
Duoxetine (SNRI) 3533
Venlafaxine (SNRI) >10,000
Milnacipran (SNRI) >10,000
Mirtazapine (NaSSA) >10,000
The dara are from Ishima et al. (11).
SSRI: Selective serotonin reuptake inhibitor; SNRI: Serotonin norepinephrine
reuptake inhibitor; NaSSA: Noradrenaline speciﬁc serotonergic antidepressant.nerve growth factor (NGF)-induced neurite outgrowth in PC12
cells, and that their effects were antagonized by the selective
sigma-1 receptor antagonist NE-100 or sertraline (11,12). These
ﬁndings suggest that these SSRIs (ﬂuvoxamine, ﬂuoxetine, and
esciltalopram) are sigma-1 receptor agonists, and but sertraline
may act as an antagonist of sigma-1 receptor (Table 1). A study
using positron emission tomography (PET) showed that orally
administered ﬂuvoxamine bound to sigma-1 receptors in the intact
human brain (13). Therefore, it is likely that sigma-1 receptor plays
a role in the therapeutic mechanism of some SSRIs, such as ﬂu-
voxamine, ﬂuoxetine and escitalopram (7e9).2.1. Cognition
Cognitive impairment is shown in patients with a number of
neuropsychiatric diseases including schizophrenia, major depres-
sive disorder (MDD), bipolar disorder (BD), generalized anxiety
disorder (GAD), panic disorder, post-traumatic stress disorder
(PTSD), obsessive compulsive disorder (OCD), attention deﬁcit hy-
peractivity disorder (ADHD), and autism spectrum disorder (ASD)
(Fig. 1) (14). The N-methyl-D-aspartate (NMDA) receptor plays a
key role in the cognitive function as well as a number of neuro-
psychiatric diseases (15). A recent study showed that treatment
with sigma-1 receptor agonists (e.g., (þ)-SKF 10,047, PRE-084,
(þ)-pentazocine) increased the expression of GluN2A and GluN2B
subunits of the NMDA receptor, as well as postsynaptic density
protein 95 (PSD-95) in the rat hippocampus (16). Furthermore,
activation of sigma-1 receptor chaperone leads to an increased
interaction between GluN2 subunits and sigma-1 receptor, and
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These ﬁndings suggest that sigma-1 receptor may play an impor-
tant role in the NMDA receptor-mediated functions such as
cognition.
Previously, we reported that, ﬂuvoxamine, but not sertraline or
paroxetine, could improve NMDA receptor antagonist phencycli-
dine (PCP)-induced cognitive deﬁcits in mice, and that NE-100
signiﬁcantly antagonized this effect (17,18). Two case reports from
Chiba University (Japan) showed that ﬂuvoxamine improved
cognitive impairment in patients with schizophrenia. A subsequent
randomized, double-blind, placebo-controlled study showed no
major beneﬁt for ﬂuvoxamine in alleviating cognitive impairment
in medicated patients with schizophrenia. However, secondary
analysis found improved executive function with ﬂuvoxamine
treatment (19). Further large scale studies to conﬁrm the effects of
SSRIs with sigma-1 receptor agonism on cognitive impairment will
be needed (8,19).
2.2. Delirium
Delirium and depression are complex neuropsychiatric symp-
toms common in the elderly, and are associated with poor health-
care outcomes (20). The pathophysiology of delirium is still not
clearly understood. Accumulating evidence suggests that drug
toxicity, inﬂammation and acute stress responses all contribute to
the disruption of neurotransmitters, such as acetylcholine, gluta-
mate, g-aminobutyric acid, dopamine, serotonin and norepineph-
rine, and consequently, to the development of delirium (20,21).
There are case reports which show beneﬁcial effects for ﬂu-
voxamine in treating delirium in patients with Alzheimer's disease,
patients in intensive care units, and elderly patients with post-
operative delirium (21). It is currently unclear whether the actions
of ﬂuvoxamine against delirium aremediated by sigma-1 receptors.
Evidence points towards sigma-1 receptor agonism, since sigma-1
receptors regulate a number of neurotransmission pathways,
including those in cognition (5,7,9). These case reports suggest that
ﬂuvoxamine may be a potential agent for the treatment of delirium
in elderly people, with minimal side effects (21). Nonetheless, a
further randomized double-blind, placebo-controlled study is
needed to verify this hypothesis.
2.3. Post-stroke depression
Post-stroke depression is a common and distressing complica-
tion of stroke, and is often under-recognized and under-treated.
Although SSRIs are widely used for treatment of post-stroke
depression, their psychopharmacology is quite heterogeneous.
Recently,Omiet al. (22) reported thatﬂuvoxaminecould alleviateER
stress via induction of sigma-1 receptor chaperone, and that treat-
mentwithﬂuvoxamine reduced the infarct area inmousebrain after
focal cerebral ischemia. Therefore, it is likely that ﬂuvoxamine
would be a potential therapeutic drug for post-stroke depression
since this is a SSRI with a sigma-1 receptor chaperone activity.
3. Donepezil
Donepezil is the most widely prescribed drug for Alzheimer's
disease. The main mechanism of action through which it inﬂuences
cognition and function is presumed to be the inhibition of acetyl-
cholinesterase (AChE) in the brain; however, donepezil binds to
sigma-1 receptor in the brain (IC50 ¼ 29.12 nM)(23). We reported
that donepezil, but not physostigmine (AChE inhibitor), signiﬁ-
cantly potentiated the NGF-induced neurite outgrowth in PC12
cells, and that potentiation of NGF-induced neurite outgrowth by
donepezil was blocked by NE-100 (24). Furthermore, we reportedthat PCP-induced cognitive deﬁcits in mice were improved after
subsequent subchronic administration of donepezil, and that NE-
100 signiﬁcantly antagonized its effect (23). Moreover, a PET
study demonstrated that oral administration of donepezil binds to
sigma-1 receptor in the intact human brain (25). These ﬁndings
suggest that sigma-1 receptor chaperone activity may be involved
in the therapeutic mechanisms of donepezil in humans (23e25).
4. Ifenprodil
Ifenprodil has been used as a cerebral vasodilator in a limited
number of countries, including Japan and France. It acts as a pro-
totypical antagonist of the NMDA receptor, GluN2B subunit. As well
as binding to the a1 adrenergic receptor and NMDA receptor an-
tagonists, ifenprodil also binds to sigma-1 (Ki ¼ 13.0 nM) and
sigma-2 receptors (Ki ¼ 1.89 nM) (26). Ifenprodil signiﬁcantly
potentiated NGF-induced neurite outgrowth, in a concentration-
dependent manner. In contrast, the a1 adrenergic receptor antag-
onist, prazosin and the NMDA receptor GluN2B antagonist Ro 25-
6981 did not alter NGF-induced neurite outgrowth (27). Potentia-
tion of NGF-induced neurite outgrowth mediated by ifenprodil was
signiﬁcantly antagonized by co-administration of NE-100, but not
the sigma-2 receptor antagonist SM-21. These ﬁndings suggest that
ifenprodil acts as a sigma-1 receptor agonist (27).
PTSD is highly prevalent among women who have experienced
childhood abuse. Re-experiencing the trauma (“ﬂashbacks”) is a
hallmark symptomofPTSD,but theprecisemechanisms forﬂashbacks
are currently unknown. In addition, there are currently no standard
therapeutic agents for treating ﬂashbacks associated with PTSD. Two
case reports showed that ifenprodil was effective in the treatment of
ﬂashbacks in three female PTSD patients with a history of childhood
sexual abuse (28) and three female adolescent PTSD patients with a
history of childhood abuse (29). Although the precise mechanisms
underlying thebeneﬁcial effects of ifenprodil are currentlyunclear, it is
likely that sigma-1 receptor chaperone activitymay be involved in the
mechanisms of its action (30). A randomized, double-blind placebo-
controlled study of ifenprodil in adolescent patients with PTSD is
currently underway at Chiba University (Chiba, Japan).
5. Neurosteroids
Neurosteroids are synthesized from cholesterol in the central
nervous system (CNS) and peripheral nervous systems. Su et al. (1)
reported that certain gonadal and adrenal steroids, in particular
progesterone, bind to sigma receptors in the brain and spleen, sug-
gesting a link between the endocrine, nervous, and immune sys-
tems. Dehydroepiandosterone (DHEA), the most abundant
endogenous neurosteroid, is a sigma-1 receptor agonist with mod-
erate afﬁnity (Ki ¼ 706 nM), whereas progesterone (Ki ¼ 268 or
36 nM) and testosterone (Ki¼ 1014 or 201 nM) are sigma-1 receptor
antagonists (9). Pregnenolone is also a sigma-1 receptor agonist
(Ki ¼ 3196 nM) (9). These ﬁndings suggest that, as endogenous li-
gands at sigma-1 receptor, these neurosteroids play an important
role in both the CNS and peripheral systems. Furthermore, we re-
ported that DHEA-sulfate (DHEA-S) could attenuate PCP-induced
cognitive deﬁcits in mice, and that this effect was antagonized by
treatment with NE-100, suggesting a role for sigma-1 receptor in its
mode of action (17). Taken together, it is likely that neurosteroids
with sigma-1 receptor agonism might have beneﬁcial effect in pa-
tients with a number of neuropsychiatric diseases (9).
6. Conclusion
A number of genetic and environmental insults are known to
impede the ability of cells to properly fold and post-translationally
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production of misfolded proteins (ER stress). High levels of mis-
folded proteins in the ER disrupt the ER homeostasis, and then
chronic ER stress may contribute to pathology of a number of dis-
eases. Accumulating evidence suggests the role of ER stress and the
unfolded protein response in the pathology of a number of
neuropsychiatric diseases. Considering the role of the sigma-1 re-
ceptor as a novel molecular chaperone that regulates protein
folding and degradation at the ER (3e5), the activation of sigma-1
receptor chaperone by agonists could prevent the misfolding of
proteins which play a role in the pathology of neuropsychiatric
diseases. The preclinical ﬁndings suggest that the activation of
sigma-1 receptor chaperone by agonists, including ﬂuvoxamine
and DHEA (or DHEA-S), could produce neuroprotective effects in
rodent models. Therefore, the activation of sigma-1 receptor
chaperone by sigma-1 receptor agonists (e.g., ﬂuvoxamine, ﬂuox-
etine, escitalopram, donepezil, ifenprodil) and endogenous neuro-
steroids (e.g., DHEA, DHEA-S, pregnenolone) might produce
beneﬁcial effects in patients with a number of neuropsychiatric
diseases (Fig. 1).
Conﬂict of interest
Dr. Hashimoto has served as a scientiﬁc consultant to Astellas,
Dainippon Sumitomo, and Taisho, and he has also received research
support from Abbvie, Dainippon Sumitomo, Otsuka, and Taisho.
Acknowledgments
This study was supported by a Grant-in-Aid for Scientiﬁc
Research on Innovative Areas of the Ministry of Education, Culture,
Sports, Science, and Technology, Japan (to K.H., #24116006).
References
(1) Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link
between endocrine, nervous, and immune systems. Science. 1988;240:
219e221.
(2) Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, et al.
Puriﬁcation, molecular cloning, and expression of the mammalian sigma1-
binding site. Proc Natl Acad Sci U S A. 1996;93:8072e8077.
(3) Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion
interface regulate Ca2þ signaling and cell survival. Cell. 2007;131:596e610.
(4) Su TP, Hayashi T, Maurice T, Buch S, Ruoho AE. The sigma-1 receptor chap-
erone as an inter-organelle signaling modulator. Trends Pharmacol Sci.
2010;31:557e566.
(5) Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP. Targeting ligand-operated
chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.
Expert Opin Ther Targets. 2011;15:557e577.
(6) Hashimoto K, Ishiwata K. Sigma receptor ligands: possible application as
therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des. 2006;12:
3857e3876.
(7) Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors:
clinical implications of their relationship. Cent Nerv Syst Agents Med Chem.
2009;9:197e204.
(8) Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs
for cognitive impairment in neuropsychiatric diseases. Curr Pharm Des.
2012;18:875e883.
(9) Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic
factor: emerging links between cardiovascular disease and depression. Prog
Neurobiol. 2013;100:15e29.(10) Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective sero-
tonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J
Pharmacol. 1996;307:117e119.
(11) Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with
sigma-1 receptor chaperones and their potentiation of neurite outgrowth in
PC12 cells. Eur J Pharmacol. 2014;727:167e173.
(12) Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth
factor-induced neurite outgrowth by ﬂuvoxamine: role of sigma-1 receptors,
IP3 receptors and cellular signaling pathways. PLoS One. 2008;3:e2558.
(13) Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. High
occupancy of sigma-1 receptors in the human brain after single oral admin-
istration of ﬂuvoxamine: a positron emission tomography study using [11C]
SA4503. Biol Psychiatry. 2007;62:878e883.
(14) Millan MJ, Agid Y, Brüne M, Bullmore ET, Carter CS, Clayton NS, et al. Cognitive
dysfunction in psychiatric disorders: characteristics, causes and the quest for
improved therapy. Nat Rev Drug Discov. 2012;11:141e168.
(15) Hashimoto K. Targeting of NMDA receptors in the new treatment of schizo-
phrenia. Expert Opin Ther Targets. 2014;18:1049e1063.
(16) Pabba M, Wong AY, Ahlskog N, Hristova E, Biscaro D, Nassrallah W, et al.
NMDA receptors are upregulated and trafﬁcked to the plasma membrane
after sigma-1 receptor activation in the rat hippocampus. J Neurosci. 2014;34:
11325e11338.
(17) Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deﬁcits in mice
are improved by subsequent subchronic administration of ﬂuvoxamine: role
of sigma-1 receptors. Neuropsychopharmacology. 2007;32:514e522.
(18) Ishima T, Fujita Y, Kohno M, Kunitachi S, Horio M, Takatsu Y, et al.
Improvement of phencyclidine-induced cognitive deﬁcits in mice by subse-
quent subchronic administration of ﬂuvoxamine, but not sertraline. Open Clin
Chem J. 2009;2:7e11.
(19) Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, et al.
A randomized, double-blind, placebo-controlled trial of ﬂuvoxamine in pa-
tients with schizophrenia: a preliminary study. J Clin Psychopharmacol.
2012;32:593e601.
(20) O'Sullivan R, Inouye SK, Meagher D. Delirium and depression: inter-
relationship and clinical overlap in elderly people. Lancet Psychiatry.
2014;1:303e315.
(21) Hashimoto K, Furuse T. Sigma-1 receptor agonist ﬂuvoxamine for delirium in
older adults. Int J Geriatr Psychiatry. 2012;27:981e983.
(22) Omi T, Tanimukai H, Kanayama D, Sakagami Y, Tagami S, Okochi M, et al.
Fluvoxamine alleviates ER stress via induction of sigma-1 receptor. Cell Death
Dis. 2014;5:e1332.
(23) Kunitachi S, Fujita Y, Ishima T, Kohno M, Horio M, Tanibuchi Y, et al. Phen-
cyclidine-induced cognitive deﬁcits in mice are ameliorated by subsequent
subchronic administration of donepezil: role of sigma-1 receptors. Brain Res.
2009;1279:189e196.
(24) Ishima T, Nishimura T, Iyo M, Hashimoto K. Potentiation of nerve growth
factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1
receptors and IP3 receptors. Prog Neuropsychopharmacol Biol Psychiatry.
2008;32:1656e1659.
(25) Ishikawa M, Sakata M, Ishii K, Kimura Y, Oda Y, Toyohara J, et al. High occu-
pancy of sigma1 receptors in the human brain after single oral administration
of donepezil: a positron emission tomography study using [11C]SA4503. Int J
Neuropsychopharmacol. 2009;12:1127e1131.
(26) Hashimoto K, London ED. Interactions of erythro-ifenprodil, threo-ifenprodil,
erythro-idoifenprodil, and eloprodil with subtypes of sigma receptors. Eur J
Pharmacol. 1995;273:307e310.
(27) Ishima T, Hashimoto K. Potentiation of nerve growth factor-induced neurite
outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptors.
PLoS One. 2012;7:e37989.
(28) Kishimoto A, Kaneko M, Gotoh Y, Hashimoto K. Ifenprodil for the treatment of
ﬂashbacks in female posttraumatic stress disorder patients with a history of
childhood sexual abuse. Biol Psychiatry. 2012;71:e7e8.
(29) Sasaki T, Hashimoto K, Okawada K, Tone J, Machizawa A, Tano A, et al. Ifen-
prodil for the treatment of ﬂashbacks in adolescent female posttraumatic
stress disorder patients with a history of abuse. Psychother Psychosom.
2013;82:344e345.
(30) Hashimoto K, Sasaki T, Kishimoto A. Old drug ifenprodil, new hope for PTSD
with a history of childhood abuse. Psychopharmacology (Berl). 2013;227:
375e376.
